Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma.
Article
in English
| IMSEAR
| ID: sea-45854
ABSTRACT
Fifteen patients with histologically proven metastatic or unresectable renal cell carcinoma were enrolled for a phase II trial of Interferon-alpha 2b (> or = 6 x 10(6) U/m2) plus megestrol acetate (160 mg/day). A response rate of 14.3 per cent was achieved in this study. We observed weight gain (median 3.2 kilogram; range 1.1 to 6.9) in 5 patients, and stable weight in 5 of the 14 patients who completed the protocol. Weight gain occurred regardless of extent of metastasis or response to interferon. Our data suggest a possible role for megestrol acetate in alleviating anorexia and weight loss in patients with renal cell carcinoma undergoing interferon treatment. Further clinical trials are clearly warranted.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Aged
/
Female
/
Humans
/
Male
/
Carcinoma, Renal Cell
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Rate
/
Treatment Outcome
/
Interferon-alpha
/
Megestrol Acetate
Type of study:
Practice guideline
Language:
English
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS